Drugs / Hemay007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02603185 | Jan 2017 → Mar 2018 | inflammatory bowel disease | Hemay Pharmaceutical PTY. LTD. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05247216 | Mar 2021 → Jun 2023 | rheumatoid arthritis | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03977480 Comparator | Aug 2019 → Aug 2022 | ulcerative colitis | Tianjin Hemay Pharmaceutical Co., Ltd | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03977480 ↗ |
| Route | Oral | “Hemay007 tablets will be taken orally” NCT02603185 ↗ |